Key result
Down-regulated lysophosphatidylcholines in hypertensives are linked to ~280% higher risk of early vascular aging.
Why the study?
Arterial stiffening is a hallmark of early vascular aging (EVA) and an independent predictor of cardiovascular morbidity and mortality, but plasma metabolites associated with EVA syndrome in hypertension remain to be identified.
Are specific plasma metabolites associated with early vascular aging (EVA) syndrome in individuals with hypertension?
Case-Control (n=152)
Are specific plasma metabolites associated with early vascular aging (EVA) syndrome in individuals with hypertension?
Effect estimate: OR 3.8 (95% CI 1.7 - 8.5)
p-value: p=<.001
Down-regulated plasma lysophosphaditylcholines are associated with a significantly higher risk of early vascular aging in hypertensive patients, suggesting their potential as novel biomarkers.
No takes yet. Share an insight, caveat, or question.
May flag higher early vascular aging risk in hypertension; leaves biomarker role open for prospective validation.
Polonis et al. (2020) conducted a case-control in Hypertension (n=152). Down-regulated lysophosphatidylcholines (LPCs) vs. Higher LPC levels was evaluated on Early vascular aging (EVA) status (OR 3.8, 95% CI 1.7 - 8.5, p=<.001). Hypertensive individuals with 4 down-regulated lysophosphatidylcholines had a higher risk of early vascular aging compared to those with higher levels (OR 3.8; 95% CI 1.7-8.5; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: